Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05423847
Other study ID # CGRB11362
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 14, 2021
Est. completion date October 14, 2025

Study information

Verified date June 2022
Source Centre Hospitalier Universitaire Vaudois
Contact Noémie Boillat-Blanco, MD-PhD, PD
Phone +41 (0)79 556 16 86
Email noemie.boillat@chuv.ch
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In Sub-Saharan Africa, lower respiratory tract infections (LRTIs) and tuberculosis (TB) jointly are the leading cause of overall mortality. There is a need to integrate sustainable triage and management strategies into standard care. The TrUST study investigates the utility of point-of-care ultrasound (POCUS) for diagnosis and prognosis of LRTIs in TB endemic regions in the outpatient triage setting. Automated interpretation of POCUS by artificial intelligence (AI) may further standardize and improve its predictive utility as well as facilitate its implementation into usual practice.


Description:

Design International multicentre prospective cohort study Setting This study aims to explore the performance of POCUS in a pre-hospital setting in countries with different prevalences of HIV: South- Africa (high prevalence), Benin (low prevalence) and Mali (low prevalence). Study procedures Pre-recruitment training Before initiating the study, participating clinicians will benefit from lung ultrasound (LUS) and POCUS protocols for extra pulmonary TB (FASH+ exam) training with a field expert. The participating clinicians are required to pass a final expert test before start of patient recruitment and to have a minimum of 20 supervised US. Inclusion (Day 0) Patients inclusion will be performed over a period of 18 to maximum 24 months. Recruitment will stop before the anticipated end if the inclusion of 1000 patients is reached. Clinical data Data collected include demographic characteristics (age, sex, occupation etc.), past medical history (previous TB, Coronavirus Disease (COVID), vaccination status, documented past episodes of COVID-19, HIV status,…), symptoms (respiratory symptoms, specific COVID-19 symptoms (from the Centers for Disease Control COVID checklist), specific pulmonary TB symptoms (from the CDC TB checklist) and routine clinical examination findings (vital parameters, oxygen saturation, lung auscultation,…). Laboratory analyses Analyses performed on site: - HIV screening with a serial two rapid test algorithm as per World Health Organization (WHO) guidelines : Screening with Alere Determine combo®; if positive, confirmation by a second rapid test First Response® HIV 1-2-0, CD4 count and/or Viral load as per national guidelines. - Sputum for GeneXpert Mycobacterium Tuberculosis (MTB)/rifampicine (RIF) assay - Induced sputum for a new GeneXpert MTB assay if a routine spot and second morning GeneXpert MTB is negative and sputum quality was low (salivary) as per WHO consolidated guidelines - Sputum for Gram stain and standard bacteriological culture - Nasopharyngeal swab for Severe Acute Respiratory Syndrome Coronovirus (SARS-CoV-2) real-time polymerase chain reaction (RT-PCR) (Cepheid Xpert Xpress SARS-CoV-2) Since the additional diagnostic yield of mycobacterial culture is shown to be very low in adult patients with cough in Benin, it is reserved for GenXpert MTB/RIF resistant cases, specimens other than sputum (e.g. pleural effusions, where sensitivity of GeneXpert MTB/RIF is low) and patients with treatment failure. Mycobacterial culture will be done on solid medium (Löwenstein-Jensen). Analyses performed retrospectively on stored samples: - Nasopharyngeal swab: PCR for influenza - Sputum: syndromic molecular panel targeting influenza and atypical bacteria. Radiological examinations - Chest X-Ray (CXR) - face: digital format will be stored - LUS exam using a standard point-of-care ultrasound device (ultrasound-on-a-chip), LUS will be recorded according to a standard 12-point acquisition protocol with 4 additional apical sites (2 subclavicular and 2 axillary) for improved TB detection. - This involves scanning both apexes, the anterior and posterior apexes, anterior superior, anterior inferior, posterior superior, posterior inferior and lateral thorax regions - FASH plus exam using a standard point-of-care ultrasound device. The FASH plus protocol will be performed in a standardized manner as previously described. All US images captured will be digitally recorded and transferred via a secured internet connection along with relevant metadata to a secure server for storage. For study quality control purposes, the quality of the image and the interpretation of a random sample of images will be evaluated retrospectively by an experienced radiologist. Clinician-evaluated LUS and FASH All LUS and FASH exams will be read by 2 independent readers blinded to patients diagnosis and outcome. A third reader will solve discrepancies between the two readers. They will fill in a standardized LUS and FASH report. AI-evaluated LUS and FASH The US images will be further used for secondary studies developing deep learning algorithms for LUS and FASH diagnosis. Follow-up (D7 and D28) Patients will receive a follow-up phone call by the study nurse on day 7 and day 28. Data on the clinical evolution are collected: hospitalization, non-invasive ventilation, intubation, death. Follow-up of TB treatment failures and deaths until D180 TB patients will be followed in the national TB register and treatment failures will be recorded at 6 months of treatment (according to national guidelines). Deaths will be recorded until D180 as well.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date October 14, 2025
Est. primary completion date April 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Suspicion of lower respiratory tract infection (defined as presence of cough with at least one of the following: fever, dyspnea/tachypnea, sputum production, chest pain, hemoptysis or cachexia) Exclusion Criteria: - Cough/dyspnea from a definite non-infectious origin (cardiac, asthmatic...) - Inability to cooperate with ultrasound procedure - Inability to sign informed consent (third witness procedure available for illiterate patients)

Study Design


Intervention

Diagnostic Test:
POCUS
POCUS of lungs, pericardium and abdomen

Locations

Country Name City State
Benin CNHUPPC Cotonou Atlantic
Mali CHU point G Bamako
South Africa Wits Rural University Acornhoek

Sponsors (5)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Vaudois Ecole Polytechnique Fédérale de Lausanne, National University Hospital (CNHU point G), Bamako, Mali, National University Hospital for tuberculosis, Cotonou, Benin, University of Witwatersrand, South Africa

Countries where clinical trial is conducted

Benin,  Mali,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity of LUS for the detection of TB For LUS, each lung quadrant will be scored using a 6 feature LUS score (modified Soldati score) ranging from 1 (aerated lung), 2 (interstitial syndrome), 3 (sub centimeter pleural lesions), 4 (lung consolidation), 5 (pleural effusion) to 6 (pneumothorax). Sensitivity of LUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards 18 to 24 months
Primary Specificity of LUS for the detection of TB For LUS, each lung quadrant will be scored using a 6 feature LUS score (modified Soldati score) ranging from 1 (aerated lung), 2 (interstitial syndrome), 3 (sub centimeter pleural lesions), 4 (lung consolidation), 5 (pleural effusion) to 6 (pneumothorax). Sensitivity of LUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards 18 to 24 months
Primary Sensitivity of FASH PLUS for the detection of TB For the pericardial and abdominal ultrasound, a score according to the FASH PLUS protocol will be attributed ranging from 0 (no pathology) to 6 (presence of pericardial effusion, abdominal adenopathies, pleural effusion, splenic lesions, hepatic lesions, ascites). Sensitivity of FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards. 24 to 36 months
Primary Specificity of FASH PLUS for the detection of TB For the pericardial and abdominal ultrasound, a score according to the FASH PLUS protocol will be attributed ranging from 0 (no pathology) to 6 (presence of pericardial effusion, abdominal adenopathies, pleural effusion, splenic lesions, hepatic lesions, ascites). Specificity of FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards. 24 to 36 months
Primary Sensitivity of combined LUS and FASH PLUS features for the detection of TB Sensitivity of combined LUS and FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards. 24 to 36 months
Primary Specificity of combined LUS and FASH PLUS features for the detection of TB Specificity of combined LUS and FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards. 24 to 36 months
Primary Sensitivity of AI-interpreted LUS for the detection of TB LUS images will be scored binary by microbiological-label trained algorithms as TB or not TB. Prediction: Sensitivity of AI-assisted interpretation LUS for the detection of TB using microbiological tests as reference standards 24 to 36 months
Primary Specificity of AI-interpreted LUS for the detection of TB LUS images will be scored binary by microbiological-label trained algorithms as TB or not TB. Prediction: Specificity of AI-assisted interpretation LUS for the detection of TB using microbiological tests as reference standards 24 to 36 months
Primary Sensitivity of AI-interpreted FASH PLUS for the detection of TB FASH PLUS images will be scored binary by microbiological-label trained algorithms as TB or not TB. Prediction: Sensitivity of FASH PLUS for the detection of TB using microbiological tests as reference standards 24 to 36 months
Primary Specificity of AI-interpreted FASH PLUS for the detection of TB FASH PLUS images will be scored binary by microbiological-label trained algorithms as TB or not TB. Prediction: Specificity of FASH PLUS for the detection of TB using microbiological tests as reference standards 24 to 36 months
Secondary Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS to assess its feasibility, sustainability and acceptability 12 months
Secondary Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support to assess its feasibility, sustainability and acceptability 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2